Industry partnership accelerates atherosclerosis therapies to market

Celltrion signed an “incubation” agreement with Emory University to jointly research and develop new drug candidates for atherosclerosis. An incubation agreement is an open innovation arrangement in which a firm provides its resources and business capabilities, such as research facilities, workforce and operations consulting, to an external research institute. The arrangement aims to ensure the autonomy of the research while obtaining preferential rights to discuss commercializing the research output.

Under the agreement, Celltrion will share its accumulated biologics development expertise with the Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, and provide research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement.

One of the leaders of the Emory team is Dr. Hanjoong Jo, a faculty member in the MSP program.

Click here to view the full story in the Emory News Center.